dr4 receptor agonist antibodies  (Amgen)

Journal: Clinical Cancer Research

Article Title: Low-Dose 12-O-Tetradecanoylphorbol-13-Acetate Enhances Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis in Prostate Cancer Cells

doi: 10.1158/1078-0432.ccr-07-1133

Figure Lengend Snippet: Fig. 6. TPA enhancement ofTRAIL-induced apoptosis is independent of DR4 levels. A, Western blots for DR4 and DR5 levels in LNCaP cells after treatment withTRAIL orTPA. B, cell viability of LNCaP cells treated withTPA alone (100 ng/mL) or pretreated withTPA (100 ng/mL) for 24 h followed by treatment with the DR4 agonist, mapatumumab (10 Ag/mL), or the DR5 agonist, lexatumumab (10 Ag/mL), for another 48 h. C, cell viability for LNCaP cells after transfecting DR4 RNAi for16 h and then pretreated withTPA for 24 h, followed by treatment withTRAIL for 48 h. D, cell viability of LNCaP cells, which were determined after ectopic expression of DR4 for 24 h, followed by pretreatment withTPA for 24 h followed by treatment withTRAIL for an additional 48 h. C and D, insets,Western blots for DR4. GAPDHis used as loading control. Bars, SD from at least three independent experiments.

Article Snippet: Recombinant human TRAIL/TNFSF10 was obtained from R&D System Inc. TRAIL-receptor 1 (DR4) agonist monoclonal antibody, mapatumumab, and TRAIL-receptor 2 (DR5) agonist monoclonal antibody, lexatumumab, were obtained from Human Genome Sciences, Inc. Antibodies to c-Fos, Fos B, Fra-1, Fra-2, Jun B, Jun D, DR4, DR4 RNAi, and horseradish peroxidase–conjugated secondary antibodies (goat–anti-mouse, goat–anti-rabbit, and goat– anti-rat antibodies) were obtained from Santa Cruz Biotechnology, Inc. Antibody to c-Jun was from Cell Signaling.

Techniques: Western Blot, Expressing, Control